Interstitial lung disease
MONDO:0015925A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Also known as: ILD, interstitial lung disease
729 clinical trials for this condition and its sub-types, 257 tagged with Interstitial lung disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Interstitial lung disease
-
Idiopathic pulmonary fibrosis 202 trials
-
Interstitial lung disease specific to childhood 5 trials · 163 incl. sub-types
5 sub-types
- Primary interstitial lung disease specific to childhood 45 trials · 156 incl. sub-types Sub-types →
- Hermansky-Pudlak syndrome with pulmonary fibrosis 0 trials · 1 incl. sub-types Sub-types →
- Niemann-Pick disease type B 1 trial
- Familial hypocalciuric hypercalcemia 0 trials · 1 incl. sub-types Sub-types →
- Congenital emphysematous lung disease due to Filamin A loss-of-function variant 0 trials
-
Pulmonary fibrosis 140 trials · 143 incl. sub-types
6 sub-types
- Tuberculous fibrosis of lung 3 trials
- Pulmonary fibrosis and/or bone marrow failure, telomere-related 1 trial Sub-types →
- Diffuse pulmonary fibrosis 0 trials
- Graphite pneumoconiosis 0 trials
- Localized pulmonary fibrosis 0 trials
- Postinflammatory pulmonary fibrosis 0 trials
-
Bronchiolitis obliterans syndrome 42 trials · 44 incl. sub-types
2 sub-types
-
Hypersensitivity pneumonitis 25 trials · 30 incl. sub-types
14 sub-types
- Fibrotic hypersensitivity pneumonitis 9 trials
- Ventilation pneumonitis 2 trials
- Bird fancier's lung 1 trial
- Non-fibrotic hypersensitivity pneumonitis 1 trial
- Bagassosis 0 trials
- Cork-handlers' disease 0 trials
- Farmer's lung disease 0 trials
- House allergic alveolitis 0 trials
- Hypersensitivity pneumonitis, familial 0 trials
- Idiopathic chronic eosinophilic pneumonia 0 trials
- Malt worker's lung 0 trials
- Maple bark strippers' lung 0 trials
- Mushroom workers' lung 0 trials
- Sick building syndrome 0 trials
-
Secondary pulmonary hemosiderosis 0 trials · 30 incl. sub-types
1 sub-type
- Heiner syndrome 30 trials
-
Radiation pneumonitis 20 trials
-
Interstitial lung disease specific to adulthood 0 trials · 20 incl. sub-types
2 sub-types
- Pulmonary sarcoidosis 20 trials
- Langerhans cell histiocytosis specific to adulthood 0 trials Sub-types →
-
Pneumoconiosis 5 trials · 13 incl. sub-types
14 sub-types
- Asbestosis 3 trials
- Pulmonary hemosiderosis 2 trials Sub-types →
- Silicosis 2 trials Sub-types →
- Anthracosis 1 trial
- Byssinosis 1 trial
- Caplan syndrome 0 trials
- Anthracosilicosis 0 trials
- Baritosis 0 trials
- Chronic beryllium disease 0 trials
- Graphite pneumoconiosis 0 trials
- Mixed dust pneumoconiosis 0 trials
- Mixed mineral dust pneumoconiosis 0 trials Sub-types →
- Pneumoconiosis due to talc 0 trials
- Slate pneumoconiosis 0 trials
-
Inherited interstitial lung disease 5 trials · 11 incl. sub-types
13 sub-types
- Interstitial lung disease 2 2 trials
- Hermansky-Pudlak syndrome with pulmonary fibrosis 0 trials · 1 incl. sub-types Sub-types →
- Niemann-Pick disease type B 1 trial
- Rajab interstitial lung disease with brain calcifications 0 trials · 1 incl. sub-types Sub-types →
- Familial hypocalciuric hypercalcemia 0 trials · 1 incl. sub-types Sub-types →
- Pulmonary fibrosis and/or bone marrow failure, telomere-related 1 trial Sub-types →
- Lane Hamilton syndrome 0 trials
- SFTPC-related interstitial lung disease 0 trials
- Alveolar capillary dysplasia with misalignment of pulmonary veins 0 trials
- Hypersensitivity pneumonitis, familial 0 trials
- Interstitial lung disease 1 0 trials
- Interstitial lung disease due to ABCA3 deficiency 0 trials
- Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome 0 trials
-
Isolated pulmonary capillaritis 0 trials
Most studied deeper sub-types
-
Can Device-Preserved donor lungs boost transplant success?
Disease control By invitation onlyThis registry collects data on lung transplant patients whose donor lungs were preserved and transported using the LUNGguard or BAROguard devices. Researchers track outcomes such as primary graft dysfunction, rejection, survival, ICU and hospital stays, readmissions, and time on …
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New inhaled drug aims to ease lung scarring and heart strain
Disease control OngoingThis Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…
Phase 2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for lung fibrosis patients: inhaled drug tested for long-term safety
Disease control By invitation onlyThis study looks at the long-term safety of an inhaled medication called treprostinil for people with fibrotic lung diseases like idiopathic pulmonary fibrosis. About 1,850 adults who completed a prior related study will take the drug and be monitored for side effects. The goal i…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody drug aims to halt Scleroderma's damage
Disease control OngoingThis Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Smart home tech could help lung patients breathe easier at home
Disease control OngoingThis trial tests a smart home system for people with interstitial lung disease, a condition that makes breathing difficult. Participants use home devices to track their health and do exercises, with the goal of improving symptoms and reducing hospital visits. The study compares t…
Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control OngoingThis study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…
Phase 2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes on hard-to-treat muscle disease
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (muscle inflammation) that hasn't improved with standard therapies. About 21 adults will receive either this cell therapy or a comparator. The main goal is to…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a cancer drug slow lung scarring? new trial tests anlotinib for IPF
Disease control OngoingThis Phase 2 trial tests whether anlotinib, a drug currently used for cancer, can help people with idiopathic pulmonary fibrosis (IPF) or progressive fibrosis-interstitial lung disease. The study involves 30 adults aged 40-85 and measures changes in lung function over 52 weeks. P…
Phase 2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to slow lung scarring in hypersensitivity pneumonitis
Disease control OngoingThis phase 4 trial tests whether adding mycophenolate mofetil (MMF) to standard prednisolone treatment works better than prednisolone alone for fibrotic hypersensitivity pneumonitis, a lung condition where scarring makes breathing hard. About 144 adults with at least 40% predicte…
Phase 4 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for lung scarring: phase 3 trial underway
Disease control OngoingThis study tests an experimental drug, BMS-986278, in about 1057 adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. Participants receive either the drug or a placebo to see if it can slow lung function decline and is safe. The trial is …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New inhaled drug aims to help patients with lung scarring and high blood pressure
Disease control PausedThis phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…
Phase 3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Withdrawn plasma study leaves COVID-19 pneumonia treatment question unanswered
Disease control CancelledThis study aimed to test whether giving antibody-rich plasma from recovered COVID-19 patients could help hospitalized adults with pneumonia caused by the virus. The trial was withdrawn before any participants were enrolled, so no data was collected. The approach was based on the …
Phase 1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New study tracks how well nintedanib works over time for scleroderma lung disease
Disease control OngoingThis study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for lung cancer patients with scarred lungs: precision radiation trial underway
Disease control OngoingThis phase II trial tests a precise type of radiation called SABR in 39 people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. P…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 26, 2026 17:34 UTC
-
New CT tool aims to sharpen diagnosis of lung fibrosis
Diagnosis OngoingThis study is testing a new tool that uses chest CT scans to help doctors more accurately diagnose different types of pulmonary fibrosis, a lung scarring disease. Researchers will first create the tool by analyzing scans from 300 patients, then test it on 100 additional patients.…
Sponsor: Columbia University • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
New MRI technique could reveal how well lung treatments are working
Diagnosis OngoingThis study is testing a special MRI technique using inhaled xenon gas to better see changes in the lungs of people with interstitial lung disease. Researchers want to make the method consistent across different hospitals and MRI machines. The goal is to help doctors quickly tell …
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
Can a smarter oxygen device help lung disease patients move more?
Symptom relief By invitation onlyThis study tests whether using a portable oxygen concentrator (a lightweight, battery-powered device) during walking or exercise helps people with interstitial lung disease (ILD) or COPD feel less breathless and be more active in their daily lives. Twenty-four participants will t…
Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD
Symptom relief By invitation onlyMany Veterans with heart failure or COPD struggle with breathlessness, fatigue, depression, and anxiety that routine care often misses. This study tests whether a virtual team—a nurse and a social worker—can improve quality of life by helping Veterans manage their most bothersome…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
One leg at a time: new exercise hope for lung disease patients
Symptom relief OngoingThis study looks at whether training one leg at a time on a bike can help people with idiopathic pulmonary fibrosis (IPF) exercise longer. IPF makes it hard to breathe, so using fewer muscles may allow a better workout. The trial will compare one-legged cycling to the usual two-l…
Sponsor: West Park Healthcare Centre • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can remote rehab help lung patients breathe easier?
Symptom relief OngoingThis pilot study tests whether home-based or video-supervised exercise programs are acceptable and helpful for people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, asthma, and other interstitial lung diseases. Fifty participants will be randomly assigned to on…
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a radioactive tracer reveal hidden lung scarring?
Knowledge-focused OngoingThis study tests whether a radioactive tracer called 68Ga-FAPi-46 can light up areas of scarring (fibrosis) in the lungs of people with interstitial lung disease. Participants receive the tracer and undergo a PET/CT scan to see where it collects. The goal is to understand how the…
Early phase 1 • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
New Bio-Bank aims to unlock secrets of lung disease and transplants
Knowledge-focused OngoingThis study is building a bio-bank of blood samples from people who have had a lung transplant. Researchers will use these samples to study advanced lung diseases and improve transplant care. The goal is to better understand how infections and other factors affect patient outcomes…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could gentle exercise with blood flow restriction help lung disease patients?
Knowledge-focused OngoingThis study tests whether low-intensity aerobic exercise with blood flow restriction (BFR) is safe and effective for people with interstitial lung disease (ILD). BFR uses a cuff to partially block blood flow, which may help build muscle with less strain. Thirty participants will t…
Sponsor: Gazi University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New Micro-Camera could spot early lung damage in cystic fibrosis
Knowledge-focused OngoingThis study is testing a tiny camera called micro OCT that can take detailed pictures of cells inside the lungs and nose. Researchers want to see if it works well in people with cystic fibrosis and other lung conditions. The goal is to eventually use this imaging to detect early d…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Scientists hunt for clues in the blood to predict lung fibrosis outcomes
Knowledge-focused By invitation onlyThis study looks for biological markers in blood and lung samples from people with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. The goal is to find markers that can predict how the disease will progress and to group patients into subtypes. Researchers…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Lung disease study probes hidden environmental triggers
Knowledge-focused OngoingThis study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is …
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Gene study aims to unlock secrets of progressive lung disease
Knowledge-focused OngoingThis study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how in…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
9/11 Workers' lungs under the scanner: new study tracks hidden damage
Knowledge-focused By invitation onlyThis study looks at lung problems in over 2,000 World Trade Center workers and volunteers. Researchers will review chest CT scans and breathing tests to find signs of airway disease, lung scarring, and cancer. The goal is to better understand how these conditions develop and how …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI and PET scans join forces to spot lung trouble in rare muscle disease
Knowledge-focused OngoingThis study looks at 200 people with dermatomyositis, a rare muscle disease that often affects the lungs. Researchers are using special PET/CT scans and machine learning to create a model that can better predict if a patient has interstitial lung disease. The goal is to improve di…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Firefighter cancer screening study pulled before it started
Knowledge-focused CancelledThis study planned to give low-dose chest CT scans to firefighters aged 35 and older to see how many had lung cancer, other cancers, or lung diseases from job-related smoke and chemical exposure. It was withdrawn before any firefighters were enrolled, so no results are available.…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Lung cancer and scarred lungs: a dangerous duo under the microscope
Knowledge-focused OngoingThis study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study aims to improve radiotherapy for tough lung cancer cases
Knowledge-focused OngoingThis study looks at 80 lung cancer patients with complex conditions, like rare tumor types or previous radiation, to see how well radiotherapy works and what side effects occur. The goal is to gather information to help doctors make better treatment decisions for future patients.…
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC